17β-Hydroxysteroid dehydrogenase 1:2 and breast cancer recurrence: a Danish population-based study

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Pan H, Gray R, Braybrooke J, et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–1846.
   PubMed Web of Science ®Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055.
   PubMed Web of Science ®Google Scholar
• Anderson WF, Chatterjee N, Ershler WB, et al. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat. 2002;76(1):27–36.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. JCO. 2016;34(25):3069–3103.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Gradishar WJ, Anderson BO, et al. NCCN guidelines insights: breast cancer, version 3.2018. J Natl Compr Canc Netw. 2019;17(2):118–126.
   PubMed Web of Science ®Google Scholar
• Jordan VC. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer. 2014;21(3):R235–46.
   PubMed Web of Science ®Google Scholar
• Moller S, Jensen MB, Ejlertsen B, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47(4):506–524.
   PubMed Web of Science ®Google Scholar
• Aka JA, Mazumdar M, Chen CQ, et al. 17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production. Mol Endocrinol. 2010;24(4):832–845.
   PubMedGoogle Scholar
• Day JM, Foster PA, Tutill HJ, et al. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer. . 2008;122(9):1931–1940.
   PubMed Web of Science ®Google Scholar
• McNamara KM, Sasano H. The intracrinology of breast cancer. J Steroid Biochem Mol Biol. 2015;145:172–178.
   PubMed Web of Science ®Google Scholar
• Hilborn E, Stal O, Jansson A. Estrogen and androgen-converting enzymes 17beta-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17beta-hydroxysteroid dehydrogenase type 1, 2, and breast cancer. Oncotarget. 2017;8(18):30552–30562.
   PubMedGoogle Scholar
• Jansson A, Delander L, Gunnarsson C, et al. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients. Clin Cancer Res. 2009;15(10):3610–3616.
   PubMed Web of Science ®Google Scholar
• Zhang CY, Wang WQ, Chen J, et al. Reductive 17beta-hydroxysteroid dehydrogenases which synthesize estradiol and inactivate dihydrotestosterone constitute major and concerted players in ER + breast cancer cells. J Steroid Biochem Mol Biol. 2015;150:24–34.
   PubMed Web of Science ®Google Scholar
• Lash TL, Cronin-Fenton D, Ahern TP, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst. 2011;103(6):489–500.
   PubMedGoogle Scholar
• Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group–DBCG: history, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol. 2008;47(4):497–505.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Offersen BV, Overgaard J, et al. Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. Acta Oncol. 2018;57(1):3–12.
   PubMed Web of Science ®Google Scholar
• Kononen J, Bubendorf L, Kallionimeni A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844–847.
   PubMed Web of Science ®Google Scholar
• McCarty KS, Jr., Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716–721.
   PubMed Web of Science ®Google Scholar
• Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22(3):278–295.
   PubMed Web of Science ®Google Scholar
• Mansournia MA, Altman DG. Inverse probability weighting. BMJ. 2016;352:i189.
   PubMedGoogle Scholar
• Gunnarsson C, Olsson BM, Stal O. Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res. 2001;61(23):8448–8451.
   PubMed Web of Science ®Google Scholar
• Gunnarsson C, Hellqvist E, Stal O. 17beta-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. Br J Cancer. 2005;92(3):547–552.
   PubMed Web of Science ®Google Scholar